Does Bovine Lactoferrin Prevent Death Or Disability In Very Low Birthweight Infants? Childhood Follow Up In The NHMRC LIFT Study
Funder
National Health and Medical Research Council
Funding Amount
$1,474,012.00
Summary
Our international consortium of investigators proposes to undertake follow up in survivors among 1,500 very low birth weight preterm infants enrolled in the NHMRC Lactoferrin Infant Feeding Trial, which is designed to evaluate whether low-cost oral lactoferrin supplementation reduces death and disability in early childhood.
Improving The Design Of Pragmatic Clinical Trials In Children
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Whilst clinical research is designed to investigate interventions that improve patient health, to date, patients (including children) and their families have had no say in deciding what health outcomes matter most to them. The voices of patients and their families must be heard and used to inform how studies are designed if we are to achieve an improved model of health care and health service delivery. We propose to investigate and provide recommendations as to how this is best achieved.
In Vitro And In Vivo Assessment Of The Funhaler -an Innovative Therapeutic Device For Children
Funder
National Health and Medical Research Council
Funding Amount
$472,750.00
Summary
Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler ....Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler incorporates a spinning toy attached to the outside of the spacer. The toy is activated when the patient breathes through the spacer. The device has been designed to encourage children to co-operate when their asthma therapy is being delivered. The Funhaler is currently in the late development stage. We propose, firstly, to carry out in vitro assessments of drug delivery from the Funhaler compared to the two most widely available small volume spacers: the Aerochamber Plus (Trudell, Canada) and the Breath-A-Tech (Scott-Dibben, Australia). These assessments will be carried out to meet the standards of regulatory bodies worldwide (including the FDA). Secondly, we propose to perform extensive in vivo studie: filter studies to assess drug delivery to the patient; deposition studies to measure drug deposition in the lungs; and a pilot clinical trial to assess the efficacy of the device during medium to long-term use in children aged 2-8 years.Read moreRead less
A Centre For Research Excellence In Cerebral Palsy (CRE-CP)
Funder
National Health and Medical Research Council
Funding Amount
$2,622,042.00
Summary
Cerebral palsy is the most common physical disability in childhood. Our objective is to bring about a radical improvement in the treatment of individuals with cerebral palsy, both children and adults, and to determine better ways to assist their families. Emphasis will be placed on early detection of health issues and rigorous evaluation of management options. We will train more researchers and ensure that all the knowledge generated is made available to families and health care professionals.